Fr535 ORAL ALPHA 4 BETA 7 INTEGRIN ANTAGONIST AJM347 DEMONSTRATES SUSTAINED TARGET ENGAGEMENT IN A FIRST-IN-HUMAN STUDY IN HEALTHY VOLUNTEERS.